These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 8648791

  • 1. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
    Hofmockel G, Langer W, Theiss M, Gruss A, Frohmüller HG.
    J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791
    [Abstract] [Full Text] [Related]

  • 2. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH.
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Urol Oncol; 2009 Feb; 27(6):598-603. PubMed ID: 18818106
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J, Kirchner H, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():38-43. PubMed ID: 8692118
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM.
    Urology; 2004 Jun 15; 63(6):1061-5. PubMed ID: 15183950
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A, Delva R, Gomez F, Chevreau C, Douillard JY, Peny J, Coudert B, Négrier S, Groupe Français d'Immunothérapie.
    Cancer; 2002 Dec 01; 95(11):2324-30. PubMed ID: 12436438
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK, Kwak C, Lee SE.
    Urology; 2005 Sep 01; 66(3):518-22. PubMed ID: 16140069
    [Abstract] [Full Text] [Related]

  • 12. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
    Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M.
    Cancer J Sci Am; 1997 Sep 01; 3(3):157-62. PubMed ID: 9161781
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.